Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21582927 | 1.00 | METAP2 (1.00) | METAP2METAP1 | |
| SCHEMBL6477158 | 1.00 | METAP2 (1.00) | METAP2METAP1 | |
| SCHEMBL16155903 | 1.00 | METAP2 (1.00) | METAP2METAP1 | |
| SCHEMBL6477094 | 1.00 | METAP2 (1.00) | METAP2METAP1 | |
| SCHEMBL16588330 | 0.92 | METAP2 (0.84) | METAP2METAP1 | |
| SCHEMBL6486210 | 0.89 | METAP2 (0.80) | METAP2METAP1 | |
| SCHEMBL6485831 | 0.88 | METAP2 (0.78) | METAP2METAP1 | |
| SCHEMBL6477373 | 0.88 | METAP2 (1.00) | METAP2METAP1 | |
| SCHEMBL6484860 | 0.88 | METAP2 (1.00) | METAP2METAP1 | |
| SCHEMBL6484041 | 0.88 | METAP2 (1.00) | METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | claimed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | claimed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | claimed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | claimed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | claimed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | claimed |
| US-20250387350-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12419846-B2 | Biomarkers of METAP2 inhibitors and applications thereof | SYNDEVRX, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11612577-B2 | Biomarkers of METAP2 inhibitors and applications thereof | SYNDEVRX, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-20200129457-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX, INC. | 2020-04-30 | — | — | US | disclosed |
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387350-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, TGFB2, IGF2BP2 | METAP2 1/4885METAP1 9/4885 |
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, METAP1, PEBP1 | METAP2 1/4885METAP1 2/4885 |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | METAP2 1/4885METAP1 2/4885 |
| US-20200129457-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, METAP1, PCK2 | METAP2 1/4885METAP1 2/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | METAP2 1/4885METAP1 2/4885 |
| US-11612577-B2 | Biomarkers of METAP2 inhibitors and applications thereof | METAP2, METAP1, PCK2 | METAP2 1/4885METAP1 2/4885 |
| US-12419846-B2 | Biomarkers of METAP2 inhibitors and applications thereof | METAP2, METAP1, PEBP1 | METAP2 1/4885METAP1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.